Rubedo reports promising early trial results for anti-aging skin cream

Rubedo Life Sciences reported preliminary Phase 1b/2a data showing topical RLS-1496 1% cream produced a 46% reduction in actinic keratosis lesion count at four weeks in the first 18 of 24 patients evaluated, versus an 11% reduction in untreated controls. The open-label, multicenter U.S. trial assessed safety, tolerability and clinical effects on forearm lesions. RLS-1496 […] The post Rubedo reports promising early trial results for anti-aging skin cream appeared first on Longevity.Technology.